Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Eli Lilly and Company, a pharmaceutical manufacturing facility, will be receiving up to $100 million in performance-based ...

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

BRANCHBURG – Eli Lilly, a multinational pharmaceutical company headquartered in Indianapolis with $45 billion in annual sales, has confirmed that it is selling its facility on Imclone Lane off Route ...